Patents by Inventor Frederick F. Lang, JR.

Frederick F. Lang, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oncolytic adenovirus armed with therapeutic genes
    Patent number: 10080774
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 25, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano, W. K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, Jr.
  • ONCOLYTIC ADENOVIRUS ARMED WITH THERAPEUTIC GENES
    Publication number: 20150306160
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Application
    Filed: May 4, 2015
    Publication date: October 29, 2015
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Juan FUEYO, Candelaria GOMEZ-MANZANO, W. K. Alfred YUNG, Charles A. CONRAD, Frederick F. LANG, JR.
  • Oncolytic adenovirus armed with therapeutic genes
    Patent number: 9061055
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: June 23, 2015
    Assignee: Board of Regentsm The University of Texas System
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano, W.K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, Jr.
  • ONCOLYTIC ADENOVIRUS ARMED WITH THERAPEUTIC GENES
    Publication number: 20090175830
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Application
    Filed: February 12, 2009
    Publication date: July 9, 2009
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano, W.K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, JR.